美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

INVESCO BIOTECHNOLOGY & GENOME ETF

95.42

+2.052.20%

成交量：6,317

成交額：60.10萬

市值：4.14億

市盈率：53.21

高：95.42

開：94.85

低：94.77

收：93.37

52周最高：98.82

52周最低：67.69

股本：434.00萬

流通股本：434.00萬

量比：1.05

換手率：0.15%

股息：1.55

股息率：1.62%

每股收益(TTM):1.79

每股收益(LYR):18.65

淨資產收益率：24.76%

總資產收益率：0.08%

市淨率：1.67

市盈率(LYR):5.12

資料載入中...

總覽公司新聞資訊公告

Sling Therapeutics 籌集 1.23 億美元，用於推進甲狀腺相關眼病藥物的研發

百時美施貴寶就安進擬推出的Opdivo生物類似藥提起訴訟

百時美施貴寶就奧普迪沃擬推出的生物類似藥起訴安進

美國食品藥品監督管理局（FDA）批准了Scholar Rock公司的一款治療肌肉無力症的藥物

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

又爆了！集體飆漲！中東，再傳重磅

安進（AMGN）聯合療法III期臨床達主要終點

安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率

市場風向標：安進股價遭受重創

安進股價或創二十餘年來最大單日跌幅

福泰製藥(VRTX)股票9月8日盤中下跌3.06%：投資者必看的核心信息

TradingKey中文

諾華公司一款降膽固醇藥物在臨床試驗中失敗，Royalty Pharma股價下跌

安進(AMGN)股票9月8日盤中下跌8.33%：真相來了

TradingKey中文

BUZZ——美國股市動態-Sigma Lithium、Shake Shack、諾華

更正-更新版 1-安進與阿斯利康的藥物組合在晚期研究中幫助肺癌患者延長了生存期

安進股價下跌7%，創下自2025年6月以來最大單日跌幅。

更正-安進與阿斯利康聯合研發的抗癌藥物組合在晚期臨床試驗中達到了主要生存目標

安進Phase 3 Dellphi-305研究重大突破：總生存期獲益顯著優於度伐利尤單抗單藥治療

Imdelltra®聯合Imfinzi®在一線廣泛期小細胞肺癌中展現里程碑式總生存期改善

BMO下調安進及BioNTech評級至「與大市同步」

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/PBE/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PBE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBE\",,,,,undefined,":{"symbol":"PBE","market":"US","secType":"STK","nameCN":"INVESCO BIOTECHNOLOGY & GENOME ETF","latestPrice":95.42,"timestamp":1789663863486,"preClose":93.3693,"halted":0,"volume":6317,"delay":0,"changeRate":0.021963321991275573,"floatShares":4340000,"shares":4340000,"eps":1.793292,"marketStatus":"交易中","change":2.0507,"latestTime":"09-17 12:55:28 EDT","open":94.85,"high":95.42,"low":94.765,"amount":600981.56606,"amplitude":0.007015,"askPrice":95.29,"askSize":900,"bidPrice":95.08,"bidSize":500,"shortable":3,"etf":1,"ttmEps":1.793292,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":93.3693,"sharesOutstanding":3180000,"nav":93.02867,"aum":405605001.2,"dividendRate":0.016243,"bidAskSpread":0.001979,"preHourTrading":{"tag":"盘前","latestPrice":93.3693,"preClose":93.3693,"latestTime":"07:00 EDT","volume":1,"amount":93.3693,"timestamp":1789642840517,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":92.89213,"preClose":93.3693,"latestTime":"19:30 EDT","volume":12,"amount":1120.613,"timestamp":1789601405975,"change":-0.47717,"changeRate":-0.005111,"amplitude":0},"volumeRatio":1.054265,"impliedVol":0.1147,"impliedVolPercentile":0.0359},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PBE\",,,,,undefined,":{"symbol":"PBE","floatShares":4340000,"roa":"0.08%","roe":"24.76%","lyrEps":18.654418,"volumeRatio":1.054265,"shares":4340000,"dividePrice":1.5499,"high":95.42,"amplitude":0.007015,"preClose":93.3693,"low":94.765,"week52Low":67.69,"pbRate":"1.67","psRate":"241.24","week52High":98.82,"institutionHeld":0.2552,"latestPrice":95.42,"committee":-0.285714,"eps":1.793292,"divideRate":0.016243,"volume":6317,"delay":0,"ttmEps":1.793292,"open":94.85,"prevYearClose":82.15,"prevWeekClose":92.91,"prevMonthClose":96.68,"prevQuarterClose":89.6486,"fiveDayClose":93.03,"twentyDayClose":98.2643,"sixtyDayClose":85.4379},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PBE\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"PBE","amount":0.81061,"announcedDate":"2026-06-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"PBE","amount":0.08244,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"PBE","amount":0.41972,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"PBE","amount":0.23409,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"PBE","amount":0.13047,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"INVESCO BIOTECHNOLOGY & GENOME ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PBE\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-16","recordDate":"2016-09-20","paymentDate":"2016-09-30","value":0.02834,"currency":"USD"},{"executeDate":"2016-12-16","recordDate":"2016-12-20","paymentDate":"2016-12-30","value":0.1208,"currency":"USD"},{"executeDate":"2017-03-17","recordDate":"2017-03-21","paymentDate":"2017-03-31","value":0.05552,"currency":"USD"},{"executeDate":"2017-06-16","recordDate":"2017-06-20","paymentDate":"2017-06-30","value":0.21532,"currency":"USD"},{"executeDate":"2018-09-24","recordDate":"2018-09-25","paymentDate":"2018-09-28","value":0.00207,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PBE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PBE\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667074086","title":"Sling Therapeutics 籌集 1.23 億美元，用於推進甲狀腺相關眼病藥物的研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2667074086","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667074086?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 19:01","pubTimestamp":1789556485,"startTime":"0","endTime":"0","summary":"Sling Therapeutics 筹集 1.23 亿美元，用于推进甲状腺相关眼病药物的研发Kunal Das/Siddhi Mahatole路透9月16日-药物研发公司Sling Therapeutics周三表示，已筹集1.23亿美元，用于推进其用于治疗甲状腺眼病的实验性口服药物的后期临床试验。该疾病会导致眼周发炎和肿胀，进而可能引发眼球突出和视力丧失。作为此次融资协议的一部分，Sling还任命了Forbion的Regina Salvat和Sectoral Asset Management的Franois Beaubien加入其董事会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nL4T4580NN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRDN","BK4599","IE00B4R5TH58.HKD","LU2242646821.SGD","PJP","BK4566","LU1057294990.SGD","TBXU","LU1061106388.HKD","LU0122379950.USD","LU0058720904.USD","BK4588","LU0109394709.USD","LU0289739699.SGD","PBE","IE00BJT1NW94.SGD","BK4139","LU2112291526.USD","BBH","BK4585","IBB","IE00BFTCPJ56.SGD","BK4533","IE00B2B36J28.USD","BK4581","LU0320765992.SGD","IE0002141913.USD","LU1571399168.USD","LU1983299246.USD","BIB","SG9999001440.SGD","AMGN","LU2089984988.USD","LU0889565916.HKD","BK4534","LU2242652126.USD","LU1023059063.AUD","IE00BJJMRZ35.SGD","IBBQ","LU0868494617.USD","IE0009355771.USD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667267605","title":"百時美施貴寶就安進擬推出的Opdivo生物類似藥提起訴訟","url":"https://stock-news.laohu8.com/highlight/detail?id=2667267605","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667267605?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 10:15","pubTimestamp":1789524901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2322448957.HKD","LU0058720904.USD","LU0320765992.SGD","AMGN","LU0109394709.USD","LU1236620834.HKD","BMY","LU1670711123.USD","PPH","LU0868494617.USD","LU1023059063.AUD","LU2272731600.USD","BK4566","LU1983299246.USD","IHE","BK4139","BK4559","LU2125154778.USD","LU0061475181.USD","BK4585","LU0289739699.SGD","BK4533","IE00BSNM7G36.USD","LU2272731865.HKD","PBE","LU1883839398.USD","XPH","IE0009355771.USD","LU0225284248.USD","LU0225771236.USD","LU1989771016.USD","TBXU","BK4534","LU0114720955.EUR","IBB","LU1868837300.USD","FTXH","BBH","LU1236620750.USD","LU1992135399.USD","LU2473716301.USD","LU2468319806.SGD","BIB","BK4588","IE00B4R5TH58.HKD","LU1868836591.USD","LU1868836757.USD","IBBQ","LU1261432733.SGD","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667629132","title":"百時美施貴寶就奧普迪沃擬推出的生物類似藥起訴安進","url":"https://stock-news.laohu8.com/highlight/detail?id=2667629132","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667629132?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 01:29","pubTimestamp":1789493363,"startTime":"0","endTime":"0","summary":"百时美施贵宝就奥普迪沃拟推出的生物类似药起诉安进Blake Brittain路透9月15日-百时美施贵宝公司和小野制药公司已在特拉华州联邦法院起诉安进公司，试图阻止安进公司在美国推出其畅销癌症免疫疗法药物“欧迪沃”的生物类似药。百时美施贵宝和小野制药的发言人尚未立即回应置评请求。共同开发“欧狄沃”的百时美施贵宝和小野制药指控，安进的生物类似药将侵犯该药物所涉及的七项美国专利，并请求法院在专利有效期内禁止该生物类似药的销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4T4571DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0432979614.USD","LU2089984988.USD","LU0096364046.USD","BK4585","LU2125154935.USD","LU0321505439.SGD","LU0122379950.USD","PJP","LU1061106388.HKD","LU1093756168.USD","LU1868837136.USD","LU0267386448.USD","LU1868836591.USD","LU1093756325.SGD","IE0002141913.USD","LU1670711123.USD","LU0306807586.USD","LU1057294990.SGD","LU1718418525.SGD","LU2125154778.USD","BK4532","BMY","BK4599","SG9999001440.SGD","LU1868836757.USD","LU2242652126.USD","LU2596442595.SGD","LU1291159041.SGD","LU2242646821.SGD","LU1323610961.USD","LU0289739699.SGD","LU1074936037.SGD","LU1989771016.USD","LU1868836914.USD","PBE","IBB","LU1670711040.USD","LU1571399168.USD","LU0114720955.EUR","LU0306806265.USD","IHE","LU0225771236.USD","LU1868837300.USD","IE00B2B36J28.USD","LU1670710661.SGD","LU2360032135.SGD","LU1261432733.SGD","LU0985481810.HKD","LU1236620750.USD","LU1023059063.AUD","LU2133065610.SGD","LU1670710588.SGD","IBBQ","LU1983299246.USD","BK4534","LU0882574055.USD","LU2112291526.USD","LU0889565916.HKD","LU0058720904.USD","LU0321505868.SGD","IE00BJJMRZ35.SGD","LU0320765992.SGD","BK4139","BK4566","LU2468319806.SGD","LU0225284248.USD","LU0456855351.SGD","BK4533","LU1585245621.USD","BK4559","LU0237698245.USD","IE00BSNM7G36.USD","LU1430594728.SGD","04332","TBXU","BK4007","AMGN","IE00BFTCPJ56.SGD","LU1032466523.USD","BBH","LU1883839398.USD","BK4588","LU0061475181.USD","BIB","LU0109394709.USD","FTXH","IE00BFXG1179.USD","IE00B4R5TH58.HKD","LU1236620834.HKD","LU0868494617.USD","IE00BJT1NW94.SGD","IE0009355771.USD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666257258","title":"美國食品藥品監督管理局（FDA）批准了Scholar Rock公司的一款治療肌肉無力症的藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2666257258","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666257258?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 05:25","pubTimestamp":1789161915,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）批准了Scholar Rock公司的一款治疗肌肉无力症的药物路透9月11日-美国食品和药物管理局（FDA）周五批准了Scholar Rock公司开发的SRRK.O疗法，用于治疗一种会导致肌肉无力的罕见遗传性疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4T4531I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","IE00B19Z9P08.USD","BK4585","IE00B19Z9Z06.USD","IE00B894F039.SGD","BIIB","BK4533","BK4532","PBE","BK4588","LU0109394709.USD","LU0320765992.SGD","THNR","BK4139","BMED","LU0889565916.HKD","SRRK","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["GNOM","SYNB","LU2322448791.USD","TMED","LFSC","HELX","LU1992135399.USD","PBE","BK4585","FTXH","BBH","CANC","LU2272731600.USD","LU2272731865.HKD","RSPH","PSCH","IBB","IDNA","IEIH","MRNY","XBIX","BK4588","FBT","BME","RXL","AZNH","LU2322448957.HKD","PJP","XPH","IEHS","LU2272731782.SGD","WDNA","IBRN","BIOY","LU2473716301.USD","IYH","MEDI","IE00B5TLWC47.USD","BBP","MRNX","LU1992135472.HKD","BIB","PPH","PBPH","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666528665","title":"又爆了！集體飆漲！中東，再傳重磅","url":"https://stock-news.laohu8.com/highlight/detail?id=2666528665","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666528665?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 11:37","pubTimestamp":1789011420,"startTime":"0","endTime":"0","summary":"中午好，在本周二大涨之后，能化板块又爆发了！周四早盘，原油期货主力合约一度涨近10%，纯苯、苯乙烯期货主力合约涨停。截至11:30收盘，原油期货主力合约涨幅有所收窄，纯苯期货主力合约涨 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260910/c679776426.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260910/c679776426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK4581","TBXU","IE00BFTCPJ56.SGD","LU1983299246.USD","BK4588","IE00B2B36J28.USD","LU1571399168.USD","BK4139","AMGN","LU2468319806.SGD","LU0868494617.USD","BK4566","LU1061106388.HKD","LU0058720904.USD","IBB","BK4585","LU0320765992.SGD","BIB","IE0009355771.USD","LU2112291526.USD","LU1057294990.SGD","IBBQ","IE0002141913.USD","PJP","BK4533","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4599","LU2089984988.USD","LU0122379950.USD","LU2242652126.USD","PBE","SG9999001440.SGD","LU0109394709.USD","LU2242646821.SGD","LU0289739699.SGD","IE00BJT1NW94.SGD","LU1023059063.AUD","BK4534","BBH","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666712586","title":"安進（AMGN）聯合療法III期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712586","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666712586?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 16:59","pubTimestamp":1788944360,"startTime":"0","endTime":"0","summary":"金吾财经 | 安进公布，双特异性T细胞衔接器Imdelltra联合阿斯利康PD-L1抑制剂英飞凡，在广泛期小细胞肺癌的后期临床试验中实现总生存期延长。这家加州生物制药企业披露III期DeLLphi-305研究中期数据，该试验达成广泛期小细胞肺癌患者总生存期主要终点。该项全球试验评估该组合作为一线维持治疗，受试者既往接受过包含英飞凡的治疗且病情未发生进展。研究同时达成无进展生存期、客观缓解率两项次要终点。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LU0029864427.USD","IE0002141913.USD","LU0289739699.SGD","BK4568","BK4585","BK4566","LU0128525929.USD","TBXU","LU1267930573.SGD","BBH","IE00B4R5TH58.HKD","LU2112291526.USD","LU2237443895.HKD","LU2089984988.USD","IE00BJJMRZ35.SGD","SG9999001440.SGD","BIB","LU2456880835.USD","LU0708994859.HKD","LU0058720904.USD","LU0868494617.USD","BK4599","BK4139","LU2242646821.SGD","LU2468319806.SGD","IBBQ","LU1829250122.USD","LU2237443382.USD","LU1023059063.AUD","LU2462157665.USD","PJP","BK4533","IE00BFTCPJ56.SGD","LU1571399168.USD","AZN","AZNH","LU0889565916.HKD","LU0122379950.USD","IBB","BK4534","LU0432979614.USD","LU2236285917.USD","LU2242652126.USD","PBE","IE00B2B36J28.USD","LU2237443622.USD","AMGN","LU2237443978.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309213","title":"安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309213","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666309213?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 10:39","pubTimestamp":1788921579,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4534","BK4139","IE00B4R5TH58.HKD","PSYK","BK4599","LU1057294990.SGD","LU0058720904.USD","LU1023059063.AUD","LU0889565916.HKD","TBXU","AMGN","IE00B2B36J28.USD","LU2468319806.SGD","BK4585","PJP","SG9999001440.SGD","LU1983299246.USD","LU1571399168.USD","IE00BFTCPJ56.SGD","LU0109394709.USD","MDTX","LU0868494617.USD","LU0320765992.SGD","BMED","PBE","BK4588","BIB","LU1061106388.HKD","IBBQ","IBBJ","BBH","LU0122379950.USD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4566","LU2242652126.USD","IBB","IE00BJJMRZ35.SGD","BK4533","BK4581","LU2242646821.SGD","LU2112291526.USD","LU2089984988.USD","LU0289739699.SGD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112638879","title":"市場風向標：安進股價遭受重創","url":"https://stock-news.laohu8.com/highlight/detail?id=1112638879","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112638879?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 05:35","pubTimestamp":1788903338,"startTime":"0","endTime":"0","summary":"“这对安进而言，堪称最糟糕的结局。”——巴克莱分析师艾米丽·菲尔德如此评价。此前，诺华制药公布了其心脏病药物令人失望的试验结果，这一披露不仅让诺华自身承压，更给安进旗下一款重磅药物蒙上了厚厚的阴影。","market":"hk","thumbnail":"https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","IBB","IE00B2B36J28.USD","BK4139","LU2468319806.SGD","TBXU","IE00BJT1NW94.SGD","LU2242646821.SGD","BK4599","LU0320765992.SGD","LU2112291526.USD","LU0868494617.USD","IE0002141913.USD","BK4534","BK4566","LU1983299246.USD","IE00B4R5TH58.HKD","LU2089984988.USD","BK4533","LU0122379950.USD","BIB","BK4581","SG9999001440.SGD","PBE","LU1571399168.USD","BK4588","LU1061106388.HKD","LU0289739699.SGD","LU0058720904.USD","IBBQ","BK4585","LU0889565916.HKD","LU1023059063.AUD","PJP","IE00BJJMRZ35.SGD","BBH","IE00BFTCPJ56.SGD","AMGN","LU2242652126.USD","LU1057294990.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111756325","title":"安進股價或創二十餘年來最大單日跌幅","url":"https://stock-news.laohu8.com/highlight/detail?id=1111756325","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111756325?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 02:23","pubTimestamp":1788891793,"startTime":"0","endTime":"0","summary":"安进公司股价近期重挫逾9%，这一跌幅令这家生物技术巨头有望迎来自2000年10月以来最惨淡的单日表现。此番暴跌的导火索，源于诺华制药宣布其心脏病药物pelacarsen在降低心血管事件风险方面未能优于安慰剂，试验宣告失败。周二，礼来股价小幅下挫1.9%。安进的跌势因BMO资本市场的下调评级而进一步加剧，使其沦为标普500指数和纳斯达克100指数中的最大输家。","market":"hk","thumbnail":"https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/95977f976807e41662cc4b3ba02269af"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","LU0868494617.USD","LU1023059063.AUD","LU1057294990.SGD","LU2112291526.USD","IBBQ","LU0122379950.USD","LU1571399168.USD","LU0889565916.HKD","AMGN","PJP","BK4533","BK4599","IE0009355771.USD","SG9999001440.SGD","LU0289739699.SGD","LU2242652126.USD","BK4566","IBB","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4534","LU2089984988.USD","BIB","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","04332","BK4139","LU0109394709.USD","LU0320765992.SGD","BK4585","PBE","LU0058720904.USD","LU2468319806.SGD","LU1061106388.HKD","BK4588","IE00BJJMRZ35.SGD","IE0002141913.USD","LU1983299246.USD","BBH","LU2242646821.SGD","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374214","title":"福泰製藥(VRTX)股票9月8日盤中下跌3.06%：投資者必看的核心信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374214","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374214?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 02:16","pubTimestamp":1788891392,"startTime":"0","endTime":"0","summary":"• Vertex 股价在反弹至接近52周高点后遭遇波动与获利回吐。\n• 对 Crinetics 的收购整合要到2029年才能实现非GAAP增盈。\n• 技术指标显示 MACD 呈中性，RSI 呈中性，威廉指标（Williams %R）呈超卖状态。","market":"hk","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156640-market-movers-vrtx-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","LU1778281490.HKD","IBBQ","LU2362541273.HKD","IE00B19Z3581.USD","LU0432979614.USD","LU2362540622.SGD","SG9999001176.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","SG9999001176.SGD","LU0079474960.USD","VRTX","IE0009355771.USD","LU0256863811.USD","GNMX","LU1674673428.USD","LU2362541513.USD","LU1674673691.USD","BK4588","IDNA","LU1093756325.SGD","TBXU","BK4139","LU0061475181.USD","LU1093756168.USD","PBE","SGXZ57979304.SGD","IBB","IE00B19Z9Z06.USD","IE00B2B36J28.USD","SG9999013999.USD","BIB","LU0234570918.USD","IE0002141913.USD","LU1035775433.USD","LU1069344957.HKD","BK4585","LU0289739699.SGD","BK4532","LU2237438978.USD","BK4533","LU1430594728.SGD","BBH","LU1585245621.USD","IE0002270589.USD","LU0417517546.SGD","LU2417539215.USD","IE00B894F039.SGD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666371445","title":"諾華公司一款降膽固醇藥物在臨床試驗中失敗，Royalty Pharma股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2666371445","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666371445?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 00:41","pubTimestamp":1788885660,"startTime":"0","endTime":"0","summary":"——Royalty Pharma** RPRX重申“其2030年投资组合收入目标为47亿美元或更高”** 计入本交易日涨幅，该股今年以来累计上涨54.7%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4T4501DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IHE","TBXU","BBH","BK4588","LU2112291526.USD","BK4533","BK4566","AMGN","BK4585","IBBQ","BIB","RPRX","PBE","LU1571399168.USD","LU1983299246.USD","LU0289739699.SGD","BK4534","BK4139","IE00BJT1NW94.SGD","LU1061106388.HKD","LU2242646821.SGD","SG9999001440.SGD","LU0058720904.USD","LU1057294990.SGD","BK4007","LU0320765992.SGD","PJP","IE00BJJMRZ35.SGD","LU0122379950.USD","LU0868494617.USD","LU1023059063.AUD","LU0889565916.HKD","IE0009355771.USD","BK4581","IE0002141913.USD","LU0109394709.USD","IE00B4R5TH58.HKD","LU2089984988.USD","IE00B2B36J28.USD","LU2242652126.USD","IONS","IE00BFTCPJ56.SGD","BK4599","LU2468319806.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665376637","title":"安進(AMGN)股票9月8日盤中下跌8.33%：真相來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2665376637","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665376637?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 22:16","pubTimestamp":1788876978,"startTime":"0","endTime":"0","summary":"• 诺华 pelacarsen 试验失败，加大了安进竞品 olpasiran 的临床不确定性。\n• 出于对估值的担忧，BMO Capital 将安进的评级从“跑赢大盘”下调至“与大盘持平”。\n• 技术指标显示，安进的 RSI 为 40.256，威廉指标（Williams %R）为 97.857。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156239-market-movers-amgn-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TBXU","BK4585","LU0109394709.USD","BBH","AMGN","BK4533","LU2242646821.SGD","LU1983299246.USD","BK4599","IE0002141913.USD","BK4139","LU0320765992.SGD","LU1061106388.HKD","IE00BJJMRZ35.SGD","BK4581","IE0009355771.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU1571399168.USD","LU2112291526.USD","PJP","BK4588","IBB","LU0868494617.USD","BK4566","LU2242652126.USD","IBBQ","LU0289739699.SGD","LU0122379950.USD","LU1057294990.SGD","IE00B2B36J28.USD","BIB","LU0058720904.USD","LU2089984988.USD","LU2468319806.SGD","LU1023059063.AUD","BK4534","PBE","LU0889565916.HKD","IE00BFTCPJ56.SGD","SG9999001440.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375206","title":"BUZZ——美國股市動態-Sigma Lithium、Shake Shack、諾華","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375206","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375206?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:58","pubTimestamp":1788875887,"startTime":"0","endTime":"0","summary":"BUZZ——美国股市动态-Sigma Lithium、Shake Shack、诺华工作区中用于查询单只股票行情的搜索字符串：STXBZ《今日展望》通讯：https://refini.tv/3LI4BU7《晨间新闻简报》：https://refini.tv/3dKUyB8路透9月8日-周二开盘时，华尔街主要股指涨跌不一，中东地区新一轮冲突推动油价升至7月下旬以来的最高水平，而市场正在等待本周晚些时候","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4S45014M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","FRNW","LU0345769128.USD","BK4168","LU0878866978.SGD","SGXZ57979304.SGD","LU1303367103.USD","BK4592","BK4504","LU0456855351.SGD","LU1153585028.USD","LU2543165471.USD","LU0138981039.USD","LU1894683348.USD","LU2506952170.USD","BK4602","LU0234572021.USD","BK4591","LU2249611893.SGD","LU2244417387.USD","BK4581","LU0823414478.USD","BK4209","LU1718418525.SGD","BK4182","LU0289739699.SGD","LU2265009873.SGD","LU2357125470.USD","USNG","LU2098885051.SGD","IE0031619046.USD","RGTZ","PJP","LU1883839398.USD","LU0029874061.USD","SEI","LU1064131342.USD","ABM","LU2491050071.SGD","LU0345769631.USD","NVS","LU0170899867.USD","VTWG","LU2506951958.HKD","WATS","SMOG","LU1066053197.SGD","LU1023059063.AUD","LU0077335932.USD","ZAP","ILMN","LU2112291526.USD","OIH","IBB","LU0225283273.USD","LU0306807586.USD","IE00B19Z3581.USD","LU2087625088.SGD","IONS","LU0109394709.USD","CHRW","BK4131","LU1366192091.USD","IE0009354923.USD","ALV","IE00BJJMRZ35.SGD","IBAT","LU0225771236.USD","BK4588","LU1720051108.HKD","LU0353189763.USD","LU0444971666.USD","LU1093756325.SGD","LU2506951792.HKD","SG9999002224.SGD","IE00BLSP4239.USD","RGTX","LU0058720904.USD","LU0353189680.USD","LU1989772923.USD","BEX","LU1057294990.SGD","IE00B19Z3B42.SGD","LU1989771016.USD","IE00B2B36J28.USD","BK4124","LU1791710400.SGD","MEDX","LU2362540622.SGD","LU0128526141.USD","LU1642822529.SGD","LU0823414551.USD","IOYY","LU0889565916.HKD","LU0985481810.HKD","PHVS","BEG","BK4007","LU0306806265.USD","IE00B7SZL793.SGD","LU0823417653.USD","EGGY","SIMS","LU0187121727.USD","BK4170","LU0882574055.USD","LU1989764664.SGD","VCLN","BIB","LU1815336760.USD","LU2362541513.USD","IONL","BBH","LU0208291251.USD","BK4121","LU0950375773.USD","LU1988902786.USD","IE000M9KFDE8.USD","BK4179","LU2506951875.HKD","LU2362541273.HKD","LU0048584097.USD","LU0114720955.EUR","UNFI","IE00B66KJ199.SGD","IONC","LU0320765489.SGD","LU0528227936.USD","BK4532","AMGN","LU0211331839.USD","SG9999001440.SGD","LU1989772840.SGD","PTH","IBBQ","BK4541","LU0070302665.USD","BK4556","BHVN","LU0433182093.SGD","BK4597","RGTI","LU1894683264.USD","BK4505","NTLA","HYDR","BK4535","PFE","BK4120","LU1989764748.USD","SG9999003800.SGD","LU1804176565.USD","LU0444973449.USD","ICLN","PPH","WQTM","BK4141","LU0432979614.USD","SGML","LU1291159041.SGD","IE00B3T34201.USD","LU2242652126.USD","BK4568","CTEC","LU0251132253.USD","IE0002141913.USD","IE00BJT1NW94.SGD","BK4567","OZEM","DYN","IONX","BEZ","LU2294711713.HKD","BE","LU0122379950.USD","LU2357305700.SGD","SG9999011175.SGD","LU2264538146.SGD","LU2491050154.USD","LU0321505439.SGD","LU0823416689.USD","BK4102","CNRG","LU1861558580.USD","IE0034235188.USD","LU1878469433.USD","SG9999001176.SGD","UPGR","BK4139","LU0868494617.USD","LU0068578508.USD","LU1720051017.SGD","RGTC","BEC","IE00B19Z4B17.USD","LU0320765992.SGD","LU2242649171.HKD","LU0011850046.USD","SG9999001176.USD","LU0321505868.SGD","LU1093756168.USD","BK4082","LU1061106388.HKD","IE00BFTCPJ56.SGD","LU1489326972.SGD","LU2089984988.USD","LU2491049909.HKD","PBE","SG9999013999.USD","LU2596442595.SGD","LU0823417737.USD","LU2324357040.USD","BK4578","LU2468319806.SGD","BK4550","LU0225284248.USD","LU0985489474.SGD","QTUP","XES","IE00B4R5TH58.HKD","LU1548497426.USD","GNMX","RGYY","LU1861559042.SGD","SHAK","BK4548","RGTU","BK4566","IONQ","LU0266013472.USD","SG9999002232.USD","BK4533","LU1571399168.USD","LU0267386448.USD","BK4585","IE0009355771.USD","LU0238689110.USD","ROIV","LU1983299246.USD","TBXU","IE00BBT3K403.USD","IE0002270589.USD","BK4534","LU2242646821.SGD","LU0476273544.USD","GNOM","04332","IONZ","LU1791710582.SGD","LU2506952097.USD","CQTM","SRPU","BSX","LU1066051498.USD","IE00BLSP4452.SGD","LU0957808578.USD","SRPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665251375","title":"更正-更新版 1-安進與阿斯利康的藥物組合在晚期研究中幫助肺癌患者延長了生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665251375","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665251375?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:52","pubTimestamp":1788875520,"startTime":"0","endTime":"0","summary":"更新版 1-阿斯利康的联合用药方案在晚期研究中帮助肺癌患者延长了生存期全文补充了有关临床试验和背景的详细信息路透9月8日-阿斯利康AZN.L周二表示，其抗癌药物Imfinzi与安进的AMGN.O靶向免疫疗法Imdelltra联合使用，在一项晚期临床试验中显著提高了广泛期小细胞肺癌患者的总生存期。癌症治疗药物占阿斯利康销售额近一半；2025年，在该公司256.2亿美元的肿瘤产品收入中，Imfinzi贡献了60.6亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4T45013T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU0171293334.USD","BIB","LU1046234339.USD","LU0058720904.USD","LU1273509221.SGD","LU0557290698.USD","LU0887340254.USD","IBB","LU0029864427.USD","BBH","IE0009355771.USD","LU2108987350.USD","AZN.UK","LU0211328371.USD","LU0997586432.USD","LU2279689827.SGD","LU1989771016.USD","LU0158827948.USD","IE00B3T34201.USD","LU0708994859.HKD","LU1267930490.SGD","LU2089284900.SGD","BK4588","LU0889566641.SGD","LU0969580561.USD","LU1196032939.SGD","BK4585","LU0784384876.USD","LU2237443622.USD","LU2242646821.SGD","LU1153585028.USD","LU0211327993.USD","IBBQ","BK4533","PBE","AMGN","LU1267930813.SGD","LU0289739699.SGD","TBXU","LU0211326755.USD","LU0553294199.USD","LU2468319806.SGD","03165","LU0738911758.USD","PJP","LU1267930227.SGD","LU2125909593.SGD","LU0792757196.USD","LU2237443382.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375527","title":"安進股價下跌7%，創下自2025年6月以來最大單日跌幅。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375527","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375527?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:30","pubTimestamp":1788874246,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1023059063.AUD","IBBQ","AMGN","LU0889565916.HKD","BK4588","LU0320765992.SGD","IBB","LU0868494617.USD","LU0058720904.USD","BK4139","PBE","BK4533","BIB","IE0002141913.USD","IE00B4R5TH58.HKD","LU1983299246.USD","IE0009355771.USD","BK4566","LU0109394709.USD","BK4581","SG9999001440.SGD","LU1057294990.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU2242646821.SGD","LU2468319806.SGD","PJP","LU1571399168.USD","TBXU","BBH","LU2242652126.USD","LU2089984988.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","BK4585","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4599","LU2112291526.USD","LU0122379950.USD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665732793","title":"更正-安進與阿斯利康聯合研發的抗癌藥物組合在晚期臨床試驗中達到了主要生存目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2665732793","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665732793?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:14","pubTimestamp":1788873260,"startTime":"0","endTime":"0","summary":"阿斯利康抗癌药物组合在晚期临床试验中达到主要生存目标路透9月8日-阿斯利康（AstraZeneca）AZN.L周二表示，其抗癌药物Imfinzi与安进（Amgen）的AMGN.O靶向免疫疗法Imdelltra联合使用，在一项晚期临床试验中，显著提高了广泛期小细胞肺癌一线治疗患者的总生存期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4S450114:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","BK4599","LU0997586515.USD","LU2237443465.HKD","LU0029864427.USD","LU0920783379.SGD","AZN.UK","BK4139","LU0058720904.USD","LU0122379950.USD","LU1863844749.USD","LU2091194634.USD","LU1084165304.USD","IBBQ","BIB","LU0545039389.USD","LU1487256676.USD","LU1829250122.USD","IBB","IE0034235188.USD","LU0957799991.USD","LU1061106388.HKD","LU0077335932.USD","LU1003076772.USD","LU0526926950.USD","LU1880407132.USD","AMGN","LU0969580561.USD","LU0203347892.USD","PBE","LU1023059063.AUD","TBXU","LU0109394709.USD","03165","LU0784383803.USD","LU0868494617.USD","LU0289739699.SGD","LU1046234339.USD","PJP","LU2279689827.SGD","LU2355687059.USD","LU0889566641.SGD","LU2433249047.HKD","LU1170363599.USD","LU0827474353.SGD","LU2242652126.USD","LU1923622614.USD","LU1481599808.USD","BBH","LU0661504455.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115495471","title":"安進Phase 3 Dellphi-305研究重大突破：總生存期獲益顯著優於度伐利尤單抗單藥治療","url":"https://stock-news.laohu8.com/highlight/detail?id=1115495471","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115495471?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:07","pubTimestamp":1788872830,"startTime":"0","endTime":"0","summary":"安进公司宣布，其Phase 3 Dellphi-305临床研究取得重大成果——与度伐利尤单抗单独用药相比，该疗法在总生存期上展现出显著且具有临床意义的改善。这一里程碑式的发现，无疑为肿瘤治疗领域注入了新的活力与希望。尽管完整的详细数据尚未全面披露，但安进方面表示，其临床意义及安全性特征将在即将召开的重大学术会议上进行详尽报告。安进公司并未止步于此。随着研发管线的持续推进，安进正逐步兑现其以创新疗法攻克严重疾病的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU0058720904.USD","LU2112291526.USD","LU0289739699.SGD","LU0868494617.USD","IBBQ","IE00BJT1NW94.SGD","LU2468319806.SGD","PBE","BK4588","LU0122379950.USD","TBXU","IE00B4R5TH58.HKD","AMGN","IE00B2B36J28.USD","LU0109394709.USD","LU1571399168.USD","LU1061106388.HKD","IE0002141913.USD","SG9999001440.SGD","LU1057294990.SGD","BK4585","IE00BFTCPJ56.SGD","IBB","BK4533","BIB","BK4599","IE0009355771.USD","LU1023059063.AUD","LU2242646821.SGD","BBH","LU2089984988.USD","LU1983299246.USD","BK4581","LU0889565916.HKD","BK4534","LU2242652126.USD","LU0320765992.SGD","BK4566","PJP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109517247","title":"Imdelltra®聯合Imfinzi®在一線廣泛期小細胞肺癌中展現里程碑式總生存期改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1109517247","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109517247?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:04","pubTimestamp":1788872687,"startTime":"0","endTime":"0","summary":"Imdelltra®与Imfinzi®的联合疗法，于一线广泛期小细胞肺癌治疗领域，取得了具有划时代意义的总生存期提升。这一突破性进展，不仅为患者带来了新的曙光，也重塑了该领域的治疗格局。从数据层面观察，联合治疗方案的生存获益尤为显著，堪称里程碑式的成就。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BJJMRZ35.SGD","IE0009355771.USD","LU1061106388.HKD","LU1571399168.USD","LU1023059063.AUD","LU0122379950.USD","BK4585","BBH","BK4534","LU0109394709.USD","LU0289739699.SGD","LU0868494617.USD","LU2468319806.SGD","LU2242646821.SGD","IBB","LU2242652126.USD","LU1983299246.USD","LU1057294990.SGD","BK4533","PBE","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BIB","LU0058720904.USD","BK4599","AMGN","TBXU","IE00BFTCPJ56.SGD","LU2112291526.USD","BK4566","LU2089984988.USD","BK4581","LU0320765992.SGD","LU0889565916.HKD","SG9999001440.SGD","PJP","IBBQ","BK4588","IE0002141913.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665387373","title":"BMO下調安進及BioNTech評級至「與大市同步」","url":"https://stock-news.laohu8.com/highlight/detail?id=2665387373","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665387373?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:59","pubTimestamp":1788872377,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BIB","AMGN","LU1061106388.HKD","LU2242646821.SGD","BK4566","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4585","LU1023059063.AUD","IE00BJT1NW94.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU0058720904.USD","LU2468319806.SGD","IBB","BK4533","LU0122379950.USD","IE00B2B36J28.USD","BK4139","LU0868494617.USD","LU1983299246.USD","BK4588","LU2112291526.USD","IE0002141913.USD","LU2242652126.USD","BBH","IBBQ","BK4581","IE0009355771.USD","LU1057294990.SGD","LU1571399168.USD","PJP","LU0289739699.SGD","SG9999001440.SGD","LU0320765992.SGD","BK4534","LU2089984988.USD","PBE","LU0109394709.USD","BK4599","TBXU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":1,"totalSize":152,"code":"91000000","status":"200"}]}}